Search clinical trials for: NeoVas BCS

Total 3871 results

Ayala Pharmaceuticals, Inc,

Completed

A Study Of AL101In Patients With Adenoid Cystic Carcinoma (ACC) Bearing Activating Notch Mutations (ACCURACY)

Adenoid Cystic Carcinoma

United States, Canada, France, United Kingdom, Israel, Netherlands
Bristol-Myers Squibb

Available

Expanded Access for Repotrectinib
The Cleveland Clinic

Completed

A Pilot Study Swiftsure

Ventilated Patients

United States
Bristol-Myers Squibb

Completed

A Study to Evaluate the Safety, Tolerability, Kinetics and Repeatability of 18F-BMS-986327

Healthy Participants | Idiopathic Pulmonary Fibrosis (IPF)

United States
Boston Pharmaceuticals

Completed

Study to Evaluate the Efficacy, Safety, and Tolerability of BOS-589 in the Treatment of Patients With Diarrhea-predominant Irritable Bowel Syndrome (IBS-D)

Diarrhea-predominant Irritable Bowel Syndrome

United States
Bristol-Myers Squibb

Terminated

A Study of BMS-986224 in Healthy Subjects and Heart Failure Patients With Reduced Ejection Fraction

Heart Failure

Spain, United Kingdom, Netherlands, Czechia, Poland
Boston Pharmaceuticals

Completed

Study to Evaluate the Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Effects of Repeat Topical Application of BOS-356 in Subjects With Moderate to Severe Acne Vulgaris

Moderate to Severe Acne Vulgaris

United States, Canada
Boston Pharmaceuticals

Completed

Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Repeat Topical Administration of BOS-475 in Healthy Subjects and Patients With Psoriasis

Psoriasis

Australia
Bristol-Myers Squibb

Completed

An Investigational Study to Evaluate the Effects of Experimental Medication BMS-986256 in Healthy Participants

Healthy Participants

United States
Bristol-Myers Squibb

Completed

A Multiple Dose Study to Assess the Safety and Tolerability of BMS-963272 in Obese But Otherwise Healthy Adults

Obese But Otherwise Healthy Participants

United States
Bristol-Myers Squibb

Terminated

A Study of Experimental Medication BMS-986251, Taken by Mouth, in Healthy Participants and Patients With Average to Very Serious Psoriasis

Rheumatoid Arthritis | Inflammatory Bowel Diseases | Psoriasis | Nonalcoholic Steatohepatitis | Ankylosing Spondylitis

Netherlands
University of Coimbra

Completed

Rt-fMRI NF Intervention Study in ASD (NF-ASD)

Autism Spectrum Disorder
Cedars-Sinai Medical Center
Bristol-Myers Squibb

Terminated

A Study of Ixabepilone Before Surgery for High-Risk Localized Prostate Cancer

Urogenital Neoplasms | Adenocarcinoma | Carcinoma | Neoplasms, Glandular and Epithelial | Genital Neoplasms, Male | Prostatic Neoplasms | Prostatic Diseases | Genital Diseases, Male

United States
LMU Klinikum
Deutsches Zentrum für Herz-Kreislauf-Forschung (DZHK)

Completed

Vascular Healing After BVS-implantation

Coronary Heart Disease

Germany
Bristol-Myers Squibb

Completed

Pharmacokinetics, Safety, Tolerability and Pharmacodynamics of BMS-986189 in Healthy Subjects

Severe Sepsis

United States
Mackay Memorial Hospital

Unknown

Stent Placement and the Risk of New-onset AF in Patients With AMI

Acute Myocardial Infarction | Atrial Fibrillation New Onset
Bristol-Myers Squibb

Completed

A Study of BMS-986171 in Healthy People to Assess Safety, to Measure Blood Levels of Drug, and to Find Out What the Drug Does to the Body

Liver Fibrosis/NASH

United States
Bristol-Myers Squibb

Withdrawn

A Double-Blinded Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986020 Versus Placebo in Diffuse Cutaneous Systemic Sclerosis (dcSSc)

Scleroderma

United Kingdom, United States, Poland, Canada
Bristol-Myers Squibb

Completed

Pharmacokinetic and Safety Study of Daclatasvir in Patients With Renal Impairment

Hepatitis C

United States
Bristol-Myers Squibb
Exelixis

Completed

A Phase 1 Study of BMS-833923 (XL139) in Subjects With Advanced or Metastatic Cancer

Basal Cell Carcinoma (BCC) | Hedgehog Pathway | Smoothened | Basal Cell Nevoid Syndrome (BCNS)

United States, Canada
Bristol-Myers Squibb

Completed

A Phase I Study to Determine the Effect of Food on Brivanib (BMS-582664)

Tumors

United States
Bristol-Myers Squibb

Completed

Safety Study of BMS-770767 in Subjects With Hypercholesterolemia

Dyslipidemia

Canada, Australia, United States
Bristol-Myers Squibb

Completed

Safety Study to Evaluate BMS-830216 in Healthy Subjects

Obesity

United States
Bristol-Myers Squibb

Completed

Multiple Ascending Dose Study of BMS-907351 (XL184) in Patients With Solid Tumors in Japan

Neoplasms

Japan
Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.

Completed

Clinical Study of BCG Vaccine for Intradermal Injection

Tuberculosis

China
Vienna Institute for Research in Ocular Surgery

Recruiting

Performance of Two Hydrophobic IOLs

Cataract

Austria
LanZhou University

Unknown

Dendritic Cell-based Immunotherapy in Treatment Gastric Cancer

Gastric Cancer

China
Russian Academy of Medical Sciences
Pirogov Russian National Research Medical University

Completed

Efficacy of Hand Exoskeleton Controlled by BCI in Post Stroke Patients (iMove)

Poststroke/CVA Paresis

Russian Federation
Bio-Cancer Treatment International Limited

Unknown

Efficacy and Safety Study of Recombinant Human Arginase 1 in Patients With Relapsed or Refractory Acute Myeloid Leukemia

Acute Myeloid Leukemia

Hong Kong
Radboud University Medical Center

Completed

Role of BCG as Booster Vaccination

BCG Vaccination

Netherlands
Seoul National University Hospital

Completed

Comparison of NEOVIST 370 INJ.(Iopromide 768.86mg) With Ultravist 370 INJ.(Iopromide 768.86mg) in Abdominal CT

Abdominal CT
Sidney Kimmel Comprehensive Cancer Center at Johns...
Bristol-Myers Squibb

Terminated

Nivolumab With Ipilimumab in Subjects With Neuroendocrine Tumors

Neuroendocrine Tumors | Carcinoid Tumor

United States
John Kirkwood
Bristol-Myers Squibb

Active, not recruiting

Nivolumab, BMS-936558 in Combination With Relatlimab, BMS-986016 in Patients With Metastatic Melanoma Naïve to Prior Immunotherapy in the Metastatic Setting

Melanoma

United States
University of California, San Diego
Kenya Ministry of Health; Population Council Kenya

Recruiting

Adapting, Expanding and Evaluating ARCHES in Kenya

Intimate Partner Violence | Reproductive Coercion

Kenya
Bristol-Myers Squibb

Completed

An Adaptive Study to Match Patients With Solid Tumors to Various Immunotherapy Combinations Based Upon a Broad Biomarker Assessment (ADVISE)

Advanced Cancer

United States
University of Chicago
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National... and other collaborators

Active, not recruiting

Outcome of BCF Access in Hemodialysis Patients (BCF)

Dialysis | End Stage Renal Disease (ESRD) | Brachiocephalic Fistula (BCF) | Cephalic Arch Stenosis (CAS)

United States
Bristol-Myers Squibb

Completed

A Study to Evaluate the Safety, Tolerability and Drug Levels of BMS-986446 in Healthy Participants and Healthy Participants of Japanese Ethnicity

Healthy Participants

United States
Bristol-Myers Squibb

Completed

A Study to Evaluate the Drug Levels, Safety, and Tolerability of BMS-986278 in Healthy Chinese Participants

Healthy Volunteers

China
Chang Gung University of Science and Technology

Completed

Effectiveness of Basic Life Support Training for Rural Community Dwelling Elderly

Community Dwelling

Taiwan
Bristol-Myers Squibb

Completed

Study of the Safety of BMS-986259 in Participants With Post-Acute Decompensated Heart Failure

Acute Decompensated Heart Failure

United Kingdom, Israel, Argentina, Czechia, Greece, Poland
Bristol-Myers Squibb

Completed

A Study to Assess the Safety, Tolerability and Drug Levels of BMS-986172 in Healthy and Obese Participants, Including an Assessment of the Effects of Food on BMS-986172 Absorption

Healthy Participants

United States
Bristol-Myers Squibb

Completed

A Study of Experimental Medication BMS-986235 in Healthy Subjects

Mediators of Inflammation

United States
Bristol-Myers Squibb

Completed

A Study to Evaluate the Safety, Tolerability, Drug Levels, and Drug Effects of BMS-986166 in Healthy Japanese Participants

Healthy Volunteers

United States
Bristol-Myers Squibb

Completed

A Study of Experimental Medication BMS-986263 in Adults With Advanced Hepatic Fibrosis After Cure of Hepatitis C

Liver Fibrosis | Hepatic Cirrhosis

United States
Uppsala University
Abbott Medical Devices; The Medicines Company; Infraredx

Completed

PROSPECT II & PROSPECT ABSORB - an Integrated Natural History Study and Randomized Trial. (P2)

Acute Coronary Syndrome (ACS)

Sweden
Bristol-Myers Squibb

Completed

A Sub-study of BMS-986036 in Subjects With Non-Alcoholic Steatohepatitis (NASH)

Non-Alcoholic Steatohepatitis

United States
Bristol-Myers Squibb

Completed

A Study of BMS-986036 in Subjects With Non-Alcoholic Steatohepatitis (NASH)

Non-Alcoholic Steatohepatitis

United States
University of Minnesota

Completed

A Brain Centered Neuroengineering Approach for Motor Recovery After Stroke: Combined rTMS and BCI Training

Stroke | Hemiparesis

United States
Bristol-Myers Squibb

Completed

A Study of Experimental Medication BMS-986278 Given to Healthy Participants

Healthy Participants

United Kingdom, Netherlands
Poznan University of Medical Sciences

Terminated

Revascularization With BVS or CABG in Patients With Advanced CAD (RELEASE-BVS)

Multivessel Coronary Artery Disease

Poland

Search clinical trials for: NeoVas BCS

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in France

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations